BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB: IXSBF) (TSX VENTURE: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that Jeff Morhet, Chairman and CEO, will give an Open House Podium Presentation at the 15th Anniversary BioPartnering Europe Conference. The conference will be held on Tuesday, October 9th at 2:00 pm in the Abbey Room West at the Queen Elizabeth II Conference Centre in London, UK. Mr. Morhet will introduce the company and its Dynamic Cross Linking (DXL™) technology, alliances and recent clinical developments.
